The Predictive Potential of Different Molecular Markers Linked to Amikacin Susceptibility Phenotypes in Pseudomonas Aeruginosa
Overview
Authors
Affiliations
Informed antibiotic prescription offers a practical solution to antibiotic resistance problem. With the increasing affordability of different sequencing technologies, molecular-based resistance prediction would direct proper antibiotic selection and preserve available agents. Amikacin is a broad-spectrum aminoglycoside exhibiting higher clinical efficacy and less resistance rates in Ps. aeruginosa due to its structural nature and its ability to achieve higher serum concentrations at lower therapeutic doses. This study examines the predictive potential of molecular markers underlying amikacin susceptibility phenotypes in order to provide improved diagnostic panels. Using a predictive model, genes and variants underlying amikacin resistance have been statistically and functionally explored in a large comprehensive and diverse set of Ps. aeruginosa completely sequenced genomes. Different genes and variants have been examined for their predictive potential and functional correlation to amikacin susceptibility phenotypes. Three predictive sets of molecular markers have been identified and can be used in a complementary manner, offering promising molecular diagnostics. armR, nalC, nalD, mexR, mexZ, ampR, rmtD, nalDSer32Asn, fusA1Y552C, fusA1D588G, arnAA170T, and arnDG206C have been identified as the best amikacin resistance predictors in Ps. aeruginosa while faoAT385A, nuoGA890T, nuoGA574T, lptAT55A, lptAR62S, pstBR87C, gidBE126G, gidBQ28K, amgSE108Q, and rplYQ41L have been identified as the best amikacin susceptibility predictors. Combining different measures of predictive performance together with further functional analysis can help design new and more informative molecular diagnostic panels. This would greatly inform and direct point of care diagnosis and prescription, which would consequently preserve amikacin functionality and usefulness.
Antimicrobial Peptides: The Game-Changer in the Epic Battle Against Multidrug-Resistant Bacteria.
Hetta H, Sirag N, Alsharif S, Alharbi A, Alkindy T, Alkhamali A Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598464 PMC: 11597525. DOI: 10.3390/ph17111555.
Hetta H, Ramadan Y, Rashed Z, Alharbi A, Alsharef S, Alkindy T Molecules. 2024; 29(15).
PMID: 39124871 PMC: 11313800. DOI: 10.3390/molecules29153466.
Sequencing analysis and efficient biodiesel production by lipase from Pseudomonas aeruginosa.
Al-Kadmy I, Aziz S, Hussein N, El-Shafeiy S, Hamzah I, Suhail A Mol Biol Rep. 2024; 51(1):323.
PMID: 38393680 DOI: 10.1007/s11033-023-09156-z.
Al-Kadmy I, Abid S, Aziz S, Al-Kadmy Z, Suhail A, Al-Jubori S Folia Microbiol (Praha). 2023; 69(4):805-822.
PMID: 38091178 DOI: 10.1007/s12223-023-01116-1.
Phage Therapy, a Salvage Treatment for Multidrug-Resistant Bacteria Causing Infective Endocarditis.
Hetta H, Rashed Z, Ramadan Y, Al-Kadmy I, Kassem S, Ata H Biomedicines. 2023; 11(10).
PMID: 37893232 PMC: 10604041. DOI: 10.3390/biomedicines11102860.